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Gene therapyFoamy virus vectors are potent alternatives to lenti- and gamma-retroviral vectors for gene therapy. To
construct and optimize gutless feline foamy virus (FFV) replication-deﬁcient (RD) vectors, viral elements
essential for optimal efﬁcient marker gene transduction were characterized and ﬁne-mapped and packaging
clones constructed. For these purposes, new Gag and Pol expression clones which allow efﬁcient expression
of packaging proteins and vectors carrying deletions in coding and non-coding regions of the genome were
constructed and functionally evaluated. These studies demonstrate that the 5′ major splice donor (5′ SD) is
indispensable for RD vectors while deﬁned mutations introduced to inactivate the gag start codon improve
transgene delivery efﬁciency. Based on these ﬁndings, new gutless FFV vectors were generated yielding un-
concentrated vector titers above 105 transducing units (TU)/ml. By minimizing the second cis-acting
sequence in the pol gene, only 3.8 kb viral sequences are maintained in the novel gutless FFV RD vectors.
© 2009 Elsevier Inc. All rights reserved.Introduction
Gene therapy is a promising new experimental strategy to treat a
variety of human diseases including cancer, HIV/AIDS, and inherited
diseases. Among different gene transfer methods, retroviral vectors
are potent tools for this branch of molecular medicine. For
orthoretroviruses, the basic requirements for vector function have
been established over the past decades (Pfeifer and Verma, 2001). The
structural genes gag, pol, and env are in general not essential in the
vector genome, thus Gag, Pol, and Env proteins can be trans-
complemented to prepare replication-deﬁcient (RD) retroviral vec-
tors that do not further spread. In contrast, sequences at both termini
of the viral genome plus additional regions that may overlap protein-
coding sequences confer cis-acting functions essential for genomic
RNA encapsidation, reverse transcription, generation of the long
terminal repeats (LTR), and DNA integration. Therefore, these
sequences must be maintained in the vector genome. The promoters
used to express the therapeutic gene can be unrelated to the viral
vector (Pfeifer and Verma, 2001).
While stable integration and long-term expression of the trans-
gene are major advantages of retroviral vectors, insertional muta-
genesis and oncogenesis pose safety concerns for future translationalicine, Mayo Clinic College of
ogy, University of Heidelberg,
ll rights reserved.application as shown in recent clinical studies (Hacein-Bey-Abina
et al., 2003; Kaiser, 2003). Compared to lenti- and gamma-retroviral
vectors, primate FV (PFV) vectors show advantageous safety features
with weak in vitro and ex vivo integration preference into transcrip-
tional active regions (Kiem et al., 2007; Nowrouzi et al., 2006;
Trobridge et al., 2006). Recently, PFV-based vectors allowed efﬁcient
and long-term genetic modiﬁcation of canine haematopoietic stem
cells leading to recovery of diseased dogs (Bauer et al., 2008). In
addition to PFV-based vectors, a series of FFV vectors has been
constructed and applied for gene transfer and vaccination (Bastone
et al., 2007; Schwantes, Ortlepp, and Löchelt, 2002; Schwantes et al.,
2003).
Foamy viruses (FV) are the single members of the Spumaretrovir-
inae subfamily (Linial, 2007; Rethwilm, 2007) and are considered
apathogenic in either naturally infected hosts or after zoonotic
transmission into humans which adds safety features to FV vectors
(Mergia and Heinkelein, 2003). FVs are distinct from orthoretro-
viruses in many respects, for instance the Env-dependent viral
budding (Baldwin and Linial, 1998; Pietschmann et al., 1999), the
high physical and genetic stability (Rethwilm, 2007), expression of
Pol from a spliced mRNA (Bodem et al., 1996; Yu et al., 1996), the
presence of DNA genomes in released particles (Yu, Sullivan, and
Linial, 1999), and the expression of the regulatory and accessory
genes from an internal promoter (Löchelt, 2003).
FVs carry two distinct cis-acting sequence (CAS) elements that are
essential for vector function. Similar to orthoretroviruses, FV CASI is
located in the 5′ un-translated region (UTR) and extends into gag.
CASI is essential for genome encapsidation, Gag and Pol expression,
and vector function (Bastone, Bravo, and Löchelt, 2006; Heinkelein
Fig. 1. Overview of the genetic elements analyzed in the FFV-derived vectors and presentation of the new FFV packaging clones for efﬁcient Gag and Pol expression. (A) Schematic
view of the FFV genome, the pCF-7-ubi-lacZ vector with key features relevant for the current study (top), and the novel FFV Gag and Pol packaging clones showing the promoters,
CAS elements, reading frames, splice (SD/SA), and poly-A (pA) sites as well as the location of oPRE sequences. (B) 293T cells were transfected with eukaryotic FFV Gag expression
clones pCF-7-Gag, pMP-Gag-oPRE, pBC-Gag-sp, pBC-Gag-oPRE-sp, pBC-Gag-oPRE, or control plasmid pUC18 together with a Gfp expression vector. Cells were harvested 2 days p.t.
and assayed by immunoblotting for FFV Gag (top panel) and Gfp expression (bottom panel). In this and the following ﬁgures, the positions of the full-length and C-terminally
processed FFV Gag proteins are marked by a pair of horizontal lines. (C) Packaging clone pMP-Pol-oPRE but not pBC-Pol allows efﬁcient Gag expression and processing. The amounts
of the different packaging clones as well as the vector genome pCF-lac-AGC-ΔBB used for transfections are given in micrograms. Two days p.t., 293T cell lysates were assayed for Gag
expression and processing by immunoblotting using sera against FFV Gag and β-actin. (D) The infectivity of a cloned FFV genome can be suppressed by promoter competition.
Increasing molar ratios of the competing CMV-IE promoter containing plasmid pcDNA3.1 suppressed infectivity of the CMV-IE promoter-driven FFV wt genome pCF-7. Two days p.t.,
supernatants were harvested and titrated on Fe-FAB reporter cells, the mean values of two independent experiments are shown, the value for pCF-7 DNA without pcDNA3.1 was set
to 100, and the other titers are given as relative values.
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Fig. 1 (continued).
Table 1
Evaluation of different combinations of optimized FFV packaging constructsa.
Gag/Pol plasmids pBC-Pol pMP-Pol-oPRE
pBC-Gag-oPRE-sp 8.5±2.1×104 1.9±0.1×105
pMP-Gag-oPRE 4.0±2.8×104 2.5±0.7×104
a Titers of 3 μg pCF-lacZ-AGC-ΔBB co-transfected with 2 μg pBC-FFV-env and each
2 μg of the Gag and Pol packaging clones are expressed as transducing units per
milliliter (TU/ml).
210 W. Liu et al. / Virology 394 (2009) 208–217et al., 1998, 2000, 2002; Peters et al., 2005; Russell et al., 2001). An
approximately 2-kb sequence in pol represents CASII which is also
required for marker gene transfer in PFV and FFV vectors, most
probably by aiding as Pol encapsidation signal (PES) (Bastone, Bravo,
and Löchelt, 2006; Heinkelein et al., 1998, 2000, 2002; Peters et al.,
2005;Wiktorowicz et al., 2009;Wu et al., 1998). The FVmajor 5′ SD in
the R region/CASI is utilized to generate spliced pol, env, and bel
transcripts. In addition, the authentic PFV 5′ SD or a heterologous SD
are essential for efﬁcient Gag expression (Heinkelein et al., 2002) and
FFV Gag expression also depends on signals in the 5′ UTR (Bastone,
Bravo, and Löchelt, 2006).
The previous FFV ubi-lacZ vector maintained gag and pol genes
since proper truncation of Gag was not achieved due to the
overlapping essential CASI element while in pCF-7-ubi-lacZ-derived
gag and gag–pol deletion clones, fusion proteins consisting of Gag
and Pol domains exhibited trans-dominant negative effects on vector
titers (Bastone, Bravo, and Löchelt, 2006; Bastone et al., 2007). Due to
this interfering phenotype, additional analyses of essential cis-acting
elements required for vector function as well as abrogation of residual
structural gene expression were necessary to construct optimized
gutless FFV vectors.
To generate gutless FFV vectors, we ﬁrst optimized Gag and Pol
packaging clones and determined by site-directed mutagenesis that
the 5′ SD is essential for vector function while speciﬁc knock-out of
the Gag ATG start codon increases vector titers (see Fig. 1A). Finally,
non-essential regions in gag and pol between CASI and CASII (Fig. 1A,
underlined) were identiﬁed and deleted (broken line) thereby
increasing the insertional capacity and preventing replication-
competent revertants. A novel RD FFV vector with minimal viral
sequences of 3.8 kb and an insertional capacity of 8 kb was shown to
be fully functional in in vitro marker gene transfer studies.
Results
Efﬁcient FFV Gag and Pol expression clones independent of 5′ UTR
sequences
As no stable packaging cell lines are available, RD FV vectors are
prepared by transient transfection (Bastone, Bravo, and Löchelt, 2006;
Mergia and Heinkelein, 2003; Rethwilm, 2007). RD vector production
depends on sufﬁcient amounts of all viral structural proteins and full-
length genomic RNA. The current FFV Gag expression clone pCF-7-Gag
(Fig. 1A) contains the authentic FFV R and U5 regions with the FFV
CASI sequence which may compete with the vector genome for
encapsidation (Bastone, Bravo, and Löchelt, 2006). In addition, since
all previously used FFV Gag, Pol, and Env packaging clones and the
vector genome are expressed by the CMV-IE promoter (Bastone,
Bravo, and Löchelt, 2006), promoter competitionmay compromise RD
vector preparation (Schambach et al., 2006b).Expression clones pMP-Gag-oPRE and pMP-Gag (Fig. 1A) were
constructed by inserting the gag gene into an MLV-derived pMP-71
vector (Schambach et al., 2006a) containing or lacking an optimized
woodchuck hepatitis post-transcriptional regulatory element (oPRE)
in the 3′ UTR to enhance gene expression. In addition, new CMV-IE
promoter-based Gag expression clones containing an oPRE or a
splicing-competent intron of the rat pre-proinsulin II gene or both in
the 3′ UTR were constructed (Fig. 1A). 293T cells were transfected
with all Gag expression clones. Each of the new Gag expression clones
yield reproducibly more Gag protein than the previously used clone
pCF-7-Gag (Fig. 1B).
In parallel, a new Pol expression clone (pMP-Pol-oPRE) was
constructed by inserting FFV pol into pMP71-oPRE (Fig. 1A).
Expression of Pol including the viral protease (PR) by clone pMP-
Pol-oPRE was indirectly shown as Gag processing in 293T cell lysates
co-transfected with an FFV vector genome (pCF-lac-AGC-ΔBB, see
below) expressing no functional viral proteins. Compared with the
previous clone pBC-Pol, the same amount of pMP-Pol-oPRE allowed
more efﬁcient Gag expression and processing (Fig. 1C). As reduced
Gag expression is indicative of promoter competition, this effect was
studied by co-transfecting 293T cells with the CMV-IE promoter-
driven wt FFV DNA clone pCF-7 together with pcDNA3.1 DNA
containing a CMV-IE promoter. In two independent experiments, a
constant amount of pCF-7 yielded lower Gag expression and
processing (data not shown) as well as reduced FFV infectivity
when increasing amounts of pcDNA3.1 were co-transfected into 293T
cells (Fig. 1D), indicative of promoter competition.
In summary, the novel FFV packaging clones allow more efﬁcient
Gag and Pol expression due to utilization of heterologous promoters
or expression-enhancing genetic elements. The data presented here
indicate that the efﬁcacy of vector production is positively inﬂuenced
by high Gag expression but may be decreased by promoter and/or
packaging competition (see also Table 1). In this respect, the new Gag
and Pol expression vectors display advantageous features.
Site-directed mutagenesis of the 5′ SD in FFV RD vectors
The current env-bel-deleted FFV vectors maintain viral 5′ and 3′
UTR sequences and functional gag and pol genes (Bastone et al.,
Fig. 2. Mutations of the 5′ SD abolish Gag expression and vector production. (A) Gag
expression and processing defects of pSD mutants as revealed by immunoblotting of
three representative 5′ SD mutants GU to AA; AC; CC. 293T cell lysates harvested 2 days
after co-transfection with the indicated DNAs were analyzed for Gag expression and
processing using the FFV MA serum, β-actin serving as loading control was detected by
a β-actin antiserum. (B) The ﬁrst 116 nucleotides of the 5′ UTR of the wt FFV RNA
genome and the 5′SD mutant GC were analyzed with Mfold. The most stable structures
for the wt and GCmutant and an enlarged view on the sequences surrounding the 5′ SD
are shown. The GU or GC di-nucleotides located at +58–59 in the FFV RNA genomes are
marked by bars. The corresponding stems (I and II) are marked and the black triangle▶
indicates the 5′ end of the RNA genome. (C) The GC 5′ SD mutation abrogates Gag
expression and processing. 293T cells were co-transfected with 5′ SD mutant pSD-GC
and wt pCF-7-ubi-lacZ plus Gag and Pol packaging clones as indicated, harvested, and
analyzed as described above.
Fig. 3. The effect of 5′ SD mutation is caused by a defect of nucleo-cytoplasmic RNA
export. 293T cells were transfected with 6 μg of either pCF-ubi-EO or pCF-ubi-EO-GC
DNA. Cytoplasmic and nuclear fractions were prepared 2 days p.t. and RNAs were
extracted. Relative quantitative RT–PCR analyses of full-length genomic RNA in the
cytoplasmic and nuclear fractions of the transfected 293T cells were performed. GAPDH
was used as endogenous control and the full-length genomic vector RNAwas quantiﬁed
with ubiC primers. The relative amount of the wt 5′ SD clone pCF-ubi-EO (black bars)
was set to 100 and the values for the GC mutant (grey bars, pCF-ubi-EO-GC) are
expressed as relative amounts.
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vectors (see Fig. 1A) may interact with cellular splice acceptors
generating alternatively spliced transcripts upon proviral integration.
Since the 5′ SD is required for PFV vector function (Heinkelein
et al., 2002), its role in FFV vectors was determined by mutagenesis.
Similar to the cellular consensus SD sequence A/CAG↘GU, the major
5′ SD of FFV is UUGG↘GU (Bodem et al., 1996). To abolish splicing, the
essential GU di-nucleotide (underlined) was subjected to random
mutagenesis in the gag and pol containing pCF-7-ubi-lacZ vector
(Fig. 1A). Seven 5′ SD mutants were identiﬁed by DNA sequencing inwhich the GU di-nucleotide was changed to AA; AC; CC; AU; CU; GG;
CA, respectively. Due to inactivation of the 5′ SD, 293T cells were
co-transfected with the 5′ SD mutants (pSD) and Env and Pol
packaging clones to prepare vector particles. Forty-eight hours post
transfection (p.t.), cell culture supernatants were used to transduce
CRFK cells. All pSD mutants yielded extremely low titers (less than
10 transducing units (TU)/ml) when trans-complemented with Env
and Pol and co-transfections with wt pCF-7 also resulted in very low
titers (at least two logs below the parental pCF-7-ubi-lacZ vector; data
not shown). Thus, Gag expression and processing of the pSD mutants
was analyzed: Gag was barely detectable (Fig. 2A, left-hand panel)
while trans-complemented Gag was not processed even when Pol
was co-expressed (right-hand panel). As Gag processing is considered
to occur only in FV particles, the data suggest that the 5′ SD mutations
abolish proper particle assembly even when Gag, Pol, and Env
proteins are provided in trans.
Since the 5′ SD mutations may affect the RNA structure and
function of underlying cis-acting elements, folding of the ﬁrst 116
nucleotides of the wt and 5′ SD mutant genomic RNAs (5′ UTR plus 5′
SD region) was analyzed by bioinformatics (Mfold RNA structure
prediction program). In the most stable RNA fold, the GU di-
nucleotide of the wt 5′ SD is located in the second RNA stem-loop
(Fig. 2B). In contrast, this short but fully matched stem is either
disrupted or destabilized in all pSD mutants (data not shown). To
avoid alterations of the RNA secondary structure, the wt 5′ SD di-
nucleotide GU was changed to GC thereby maintaining the RNA
structure at a slightly increased stability (Fig. 2B). The novel 5′ SD
mutant pSD-GC was analyzed as described above. Similar to the other
mutants, pSD-GC did not direct Gag expression and vector titers upon
trans-complementation with Gag, Pol, and Env were very low while
Gag processing did not occur (Fig. 2C).
To exclude overall defects in vector-mediated gene expression,
lacZ expression by the ubiC promoter was measured in wt pCF-7-ubi-
lacZ- and pSD-GC-transfected cells. As comparable LacZ expression
was detected in mutant and wt-transfected 293T cells (data not
shown), an intact 5′ SD is required for FFV Gag expression and vector
genome function indicating that the 5′ SD is indispensable for
preparation of RD FFV vectors. In contrast, internal ubiC promoter-
directed gene expression is not affected by the 5′ SD mutations.
The intact 5′ SD is required for cytoplasmic accumulation of RNA vector
genomes
In all retroviruses including FVs, unspliced, full-length transcripts
are exported into the cytoplasm by special mechanisms since these
RNAs are in general retained in the nucleus (Cullen, 2003). As
impairments in nucleo-cytoplasmic export of full-length vector RNA
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we tested whether an oPRE that may enhance suboptimal gene
expression by CRM-1-dependent nuclear RNA export (Popa et al.,
2002) can restore Gag expression of the FFV 5′ SD mutants. For this
purpose, the GC mutation of the 5′ SD was introduced into the oPRE-
containing vector pCF-ubi-EO, a pCF-7-ubi-lacZ derivate with an egfp-
oPRE cassette in which the enhanced green ﬂuorescent protein gene
egfp replaced the lacZ gene (to be described elsewhere). 293T cells
were transfectedwith vectors pCF-ubi-EO, pCF-ubi-EO-GC, pCF-7-ubi-
lacZ, and pSD-GC and analyzed 48 hours p.t. Efﬁcient Gag expression
and processing were detected in cells transfected with FFV vectors
carrying the wt 5′ SD. A minor increase of Gag expression was
detected in the oPRE-containing clone pCF-ubi-EO-GC indicating that
the defect may be in fact RNA export-dependent (data not shown).
Next, the abundance of full-length genomic RNA in nuclear and
cytoplasmic fractions of pCF-ubi-EO- and pCF-ubi-EO-GC-transfected
293T cells was analyzed by relative quantitative RT–PCR. Using
reverse-transcribed vector genomes and PCR primers located in the
ubiC promoter, the 5′ SD mutant pCF-ubi-EO-GC reproducibly yielded
dramatically less cytoplasmic genomic RNA than the clone with the
wt 5′ SD (about 0.3% of the wt clone pCF-ubi-EO; Fig. 3). In contrast,
similar amounts of genomic RNAwere detected in the nuclear fraction
of transfected cells. The low abundance of cytoplasmic genomic RNA
of the 5′ SD mutant correlates with inefﬁcient Gag expression and
vector production. Thus, inactivation of the 5′ SD signiﬁcantly
decreases the amount of full-length RNA in the cytoplasm conﬁrming
that the 5′ SD has to be maintained in the RD FFV vectors for optimal
vector function.
Abrogation of truncated Gag improves gutless vector efﬁciency
RD vectors should only contain cis-acting sequences plus a
functional expression cassette for the foreign gene. As FFV CASI
extends into gag, deletion of non-essential sequences between CASI
and CASII may result in truncated Gag or Gag–Pol fusion proteins.
Since such truncated or aberrant viral proteins have trans-dominant
negative effects (Bastone, Bravo, and Löchelt, 2006; Trobridge et al.,
2002), inactivation of the gag ATG start codon (Fig. 1A) should
optimize vector production. By PCR-mediated mutagenesis, the gag
ATG in vector pCF-7-ubi-lacZ was inactivated either by introducing a
new BamHI site (ATGG to ATCC) or by randommutagenesis from ATG
to ANH (N=A; T; G; C, H=A; T; C, Fig. 4C).
None of the pCF-lac-ΔATG clones showed Gag expression in
293T cells (Fig. 4A and data not shown). Next, 293T cells were co-
transfected with the pCF-lac-ΔATG clones and pCF-7 to determine
their vector titers. Unexpectedly, the ATGG to ATCC mutation that
created a small palindromic sequence resulted in a 100-fold decreased
vector titer while the ATG to AGC mutant (pCF-lac-AGC) retained
50% of the gene transfer efﬁciency compared to the parental vector
(Fig. 4B). Other gag ATG mutants were less efﬁcient and thus not
further studied.
Due to its advantageous features, pCF-lac−AGC as well as the
parental wt vector were used as backbones to introduce further
deletions but maintaining the known CASI and CASII elements
(Fig. 1A). The deletions and their effects on Gag and Pol expression
are shown in Figs. 4C and D. As expected, Gag expression from theFig. 4. Speciﬁc knock-out mutations of the gag ATG increase titers of gutless FFV vectors. (
truncated Gag proteins. 293T cells were transfected with different gag ATG-deleted vectors (a
were analyzed for Gag expression by immunoblotting using the FFV-speciﬁc cat 8014 serum
tr.) are present, e.g., in ΔBB- but not in Gag ATG mutant AGC-ΔBB-transfected 293T cells. (
deletion mutants pCF-lac-ΔATG (ATCC) and pCF-lac-AGC. Supernatants of 293T cells taken 2
lacZ (100%) were shown; errors were given (n=3). (C) Schematic structure of the FFV
restriction sites used for mutagenesis. (D) Relative vector titers of the mutants compared to w
vectors together with packaging constructs for Gag, Pol, and Env. Two days p.t., lacZ vector ti
control (100). n=3, the means±S.D. are shown.pCF-lac-AGC derivatives was undetectable in transfected 293T cells
using cat serum 8014 and the FFV MA serum (Fig. 4A).
293T cells were co-transfected with the different deletion con-
structs and pCF-7 (3 μg each) and cell-free supernatants were assayed
on CRFK cells for LacZ transduction. Relative titers with original pCF-7-
ubi-lacZ set to 100% are shown in Fig. 4D. Compared with the parental
clone ΔBB, the gene delivery efﬁcacy of the double mutant pCF-lac-
AGC-ΔBB was about 10-fold increased due to the abrogation of
truncated Gag proteins (Fig. 4A) while clones ΔXB (which does not
express a truncated Gag protein) and AGC-ΔXB yielded almost
identical titers. Thus, mutagenesis of the gag start codon improves
vector production only when the synthesis of truncated Gag or Gag–
Pol fusion proteins is prevented. Inactivation of the gag start codon and
deletion of up to 2 kb between CASI and CASII allows efﬁcient
production of gutless vectors yielding vector titers almost comparable
to the parental vector that is only deleted in env.
Fine-mapping of CASII increases the insertional capacity of the FFV RD
vectors
Since the pCF-7-ubi-lacZ-based vectors recently used for the
identiﬁcation of FFV CASII still contained the gag ATG (Bastone, Bravo,
and Löchelt, 2006), studies were done to reﬁne CASII (Fig. 1A) using
the optimized pCF-lac-AGC vector. First, the importance of a
continuous CASII for FFV vector function was shown by deleting a
1 kb fragment between the two BstEII sites in CASII in clone AGC-ΔBB
(AGC-ΔBB-BB) which prevented vector function (Fig. 4C). Next, CASII
was minimized by PCR-based deletion mutagenesis using ﬁve sense
and three antisense primers to generate 500–700 nt-long consecutive
deletions (Fig. 5A). Eight CASII fragments from 0.6 kb to 2.1 kb were
cloned into pCF-lac-AGC-ΔBB using ﬂanking BglII and SalI sites. 293T
cells were co-transfected with the vectors and Gag, Pol, and Env
packaging clones. Parental vector pCF-lac-AGC-ΔBB with the 2.6 kb
CASII element yielded titers of 104–105 TU/ml. Truncations of 500 to
1000 bp at the 5′ and 200 bp at the 3′ end were compatible with
vector functions (Fig. 5B, clones 1A, 1B, 2A, and 2B) while larger
deletions at either end (clones 3A, 4A, 0C, and 1C) decreased vector
titers 100- to 1000-fold indicating that the minimal FFV CASII spans
map positions 3772 to 5323. Minimizing CASII to 1.5 kb resulted in
gutless FFV vectors with only 3.8 kb essential viral sequences but
maintaining parental vector titers.
Helper-free gutless ubi-lacZ vectors yield un-concentrated titers above
105 TU/ml
Finally, optimal combinations and ratios of Gag, Pol, and Env
packaging cloneswere determined. To determine the effect of Gag and
Pol over-expression on vector production, 293T cells were co-
transfected with pCF-7-ubi-lacZ containing functional gag and pol
ORFs, pBC-FFV-Env, and either Gag or Pol over-expression clones
(data not shown). Compared with controls, Gag over-expression
increased vector titers 2.3- to 2.7-fold indicating that high Gag levels
are advantageous while over-expression of Pol yielded only minor
increases in vector titers.
The gutless pCF-lac-AGC-ΔBB was then used to compare different
packaging clones. When comparing CMV-IE-based Gag and PolA) Inactivation of the gag ATG by mutagenesis abolishes expression of full-length and
s given below the blots and speciﬁed in Fig. 4C) and cellular lysates harvested 2 days p.t.
and the Gag MA antiserum (left- and right-hand panels). Truncated Gag proteins (Gag
B) Comparison of vector titers obtained with parental pCF-7-ubi-lacZ and the gag ATG
days p.t. were titrated on CRFK cells. Relative titers compared with wild type pCF-7-ubi-
deletion mutants (dashed lines represent deleted sequences) and the localization of
t pCF-7-ubi-lacZ. 293T cells were transfected with 3 μg of the indicated wt and mutant
ters were determined using CRFK cells and are expressed relative to the pCF-7-ubi-lacZ
Fig. 5. Fine-mapping and redeﬁnition of FFV CASII in the optimized gag ATG-deﬁcient pCF-lac-AGC vector backbone. (A) Schematic presentation not drawn to scale of the localization
of the primers used for amplifying deﬁned fragments of the central and 3′-terminal part of FFV pol. Primer positions are given according to the RNA genome. Amplicons tested for
CASII function were inserted via BglII (2757) to SalI (5323) sites into pCF-lac-AGC-ΔBB. The sizes of 1A, 2A, 3A, 4A, 1B, 2B, 0C, and 1C fragments are 2.1 kb, 1.5 kb, 1.0 kb, 0.6 kb, 1.8 kb,
1.4 kb, 1.7 kb, and 1.2 kb, respectively. (B) Comparison of the vector titers of the CASII mutants. 293T cells were co-transfected with each 3 μg of vector DNA and 2 μg of each
packaging clones. Supernatants were titrated on CRFK cells for LacZ expression 2 days later. pCF-lac-AGC-ΔBB was used as control. The mean values of three experiments with the
standard deviation (S.D.) are shown.
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almost similar (data not shown), possibly reﬂecting a balance between
increased expression levels of CMV-based packaging constructs versus
decreased promoter competition when using different promoters as
discussed for Fig. 1D. Finally, the effect of combining different promoters
in the packaging clones was studied. The combination of pBC-Gag-oPRE-
sp (2 μg), pMP-Pol-oPRE (2 μg) together with 2 μg pBC-FFV-env and 3 μg
pCF-lacZ-AGC-ΔBB vector DNA reproducibly yielded un-concentrated
titers above 105 TU/ml (Table 1, see above), which is comparable to the
parental pCF-7-ubi-lacZ vector. Other combinations of packaging
constructs did not further enhance vector titers.
Discussion
Efﬁcient virus replication depends not only on many factors
provided by the host cell but also on the ﬁne-tuned interplay of cis-
and trans-acting viral determinants. Both components have been
shaped by co-evolutionary processes and are thus the end-product of along-lasting optimization process. The functionality of these balanced
genetic systems is likely disturbed upon genetic manipulations
introduced to convert a viral genome into a viral vector for targeted
gene delivery and expression or for vaccine antigen expression and
presentation. The strategy to cope with this dilemma is to empirically
test replication-deﬁcient vector variants predicted to only retain
essential cis-acting elements plus the heterologous gene. The read-out
in such studies is the efﬁciency of marker gene transduction into
susceptible cells upon vector production in the presence of all essential
trans-acting functions encoded by independent genetic elements or
stably expressed by engineered producer cells.
For instance, splicing at the major 5′ SD is an important process for
viral gene expression during FV replication (Löchelt, 2003). However,
retroviral genomic RNA is not spliced and must be actively exported
from the nucleus into the cytoplasm and protected from nuclear
accumulation and degradation (Cullen, 2003). Previous studies
showed that mutations in the 5′ SD in HIV-1 vectors clearly reduce
viral RNA expression but have little effect on vector titers (Cui,
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complete intron has to be incorporated even into packaging clones in
order to rescue Gag and Pol expression (Russell et al., 2001; Trobridge
et al., 2002). Similarly, the new FFV Gag packaging clones constructed
in this study reveal that the 5′ SD of FFV can be also replaced by
intronic or post-transcriptional regulatory elements in order to
achieve efﬁcient gene expression.
In the context of the retroviral vector genome, retained 5′ SDs may
yield undesired spliced transcripts after integration, and therefore,
inactivation of the major 5′ SD in RD FFV vectors is expected to
increase vector safety. In contrast tomutagenesis of the HIV 5′ SD (Cui,
Iwakuma, and Chang, 1999), the inactivation of the FFV 5′ SD in a gag–
pol-containing vector resulted in extremely inefﬁcient Gag expression
and a more than 2-log decrease in vector titers (Figs. 2A and C). These
defects were slightly rescued by the insertion of an oPRE while
compensatory mutations to maintain the original RNA folding did
not restore the defects of the 5′ SD mutant (Figs. 2B and C) indicating
that they are not only due to destruction of essential RNA secondary
structures.
In lentiviruses and other complex retroviruses, nuclear export of
full-length RNAs is facilitated by the interaction between Rev/Rex-
like viral proteins and the corresponding RNA secondary structure-
dependent Rev/Rex-response elements (Cullen, 2003). Since FVs
apparently do not encode Rev/Rex-like proteins, alternative, unique
mechanisms may be utilized (Löchelt, 2003). The drastic decrease of
cytoplasmic full-length RNAs of the 5′ SD mutant compared with the
parental vector (Fig. 3) clearly explains the defects of Gag expression
and inefﬁcient vector production. This phenotype may be either due
to impaired nucleo-cytoplasmic transport or reduced stability of the
full-length FFV RNAs and is thus different from that described for PFV
mutants with deletions in the R region (Russell et al., 2001). In
addition, a recent study has revealed that one SD site in the gag–pol
gene determines the stability of HIV-1–RNA since mutagenesis of the
SD resulted in a dramatic reduction in the stability of these RNAs
(Lutzelberger et al., 2006). Similar functions might have been
destroyed by the 5′ SD mutagenesis in the FFV vectors, leading to
signiﬁcant decreases of full-length RNA transcripts in the cytoplasm.
Furthermore, RNA export defects plus decreased RNA stability may
have synergic effects fully explaining the low amounts of cytoplasmic
full-length vector transcripts. The above data support the view that
FVs have evolved distinct mechanisms to export full-length genomic
RNA into the cytosol. In summary, mutagenesis of the major 5′ SD is
not compatible with RD vector functions for unknown reasons and
thus, the authentic 5′ SD must be maintained for optimal RD FFV
vector function.
This as well as previous studies (Bastone, Bravo and Löchelt, 2006)
show that inactivation of the FFV gag ATG may be detrimental since
only few mutations are compatible with vector function again
supporting the concept that the integrity of speciﬁc but currently
ill-deﬁned cis-acting sequences within CASI is absolutely essential. In
the selected clones, inactivation of the gag ATG increases vector titers
by abrogating expression of aberrant Gag or Gag-Pol proteins.
To precisely map FFV CASII, PCR-mediated site-directed deletion
studies were done. Loss and gain of CASII functions were directly
measured as vector titers (Fig. 5). Compared with the parental vector
pCF-lac-AGC-ΔBB, a large genomic fragment from RNA genomic
position 2720 to 3772 in the 5′ part of the putative CASII can be
deleted from the FFV ubi-lacZ vectors. This indicates that the 5′ end of
functional FFV CASII element starts at FFV genome position 3372,
about 400 bp further downstream than recently reported (Bastone,
Bravo, and Löchelt, 2006). Only a 200-bp deletion of the 3′ part of
CASII was compatible with CASII functions while truncations of
another 700 bp from the 3′ end (from nt 4418 to 5120) led to drastic
decreases in the vector titers (Fig. 5B, clones 1B and 1C). A 3′-terminal
CASII truncation extending only to nt 4940 did not rescue the CASII
function (data not shown), indicating an important cis-acting role ofthe intact sequence. The fragment from nt 4418 to 5120 harbors
several known elements including the second poly-purine tract
(2PPT) and the splice acceptors for env. Moreover, the 3′ part may
contain the FFV PESII element, corresponding to that recently
described for PFV (Peters et al., 2005). The experimental data indicate
that FFV CASII may have at least two different functional domains
(from 3772 to 4280 and from 4418 to 5120).
In this study, the functional FFV CASII was shortened from 2.6 kb in
the pCF-lac-AGC-ΔBB construct to about 1.5 kb or 1.8 kb in vectors 2A
and 1B (Fig. 5). In the vectors with a minimized CASII, viral sequences
of about 3.8 kb are maintained, including CASI (0.7 kb), CASII (1.8 kb),
and the 5′ and 3′ LTR with the PPT (about 1.3 kb). Hence, the insertion
capacity for a foreign gene should be increased up to 8 kb in these
optimized RD FFV vectors.
While cis-acting elements of the vector genome are essential,
vector titers are also determined by molecular features of the
packaging constructs providing all trans-acting functions. Here, not
only the efﬁcacy of Gag, Pol, and Env expression but also the ratios of
the different viral components as well as the interference between the
transcription units directing packaging protein and vector genome
expression appear to be crucial for optimal titers as illustrated here by
the suppressive effects of promoter competition (Fig. 1D). The data
presented in Fig. 1 and Table 1 also indicate that advantageous
features like high Gag expression via the CMV-IE-based plasmids may
be outweighed by negative effects like promoter interference while a
lower overall Gag expression by the pMP-based constructs is
counterbalanced by a lack of promoter competition.
In the current project, gutless RD FFV vectors which are devoid of
(i) a functional gag ATG start codon and the majority of the gag gene
except minimal 5′-terminal sequences, (ii) the 5′ and central part of
pol (until residue 3220 or 3772), and (iii) the complete env–bel
region have been established and conditions for vector production
have been optimized. These novel vectors are now available for
insertion of marker and therapeutic genes in order to achieve efﬁcient
transduction of target cells in vivo and in vitro.
Materials and methods
Vectors and cells
293T and CRFK cells were cultured as reported previously (Zemba
et al., 2000). Transfection of 293T cells with plasmid DNA was
performed by calcium co-precipitation (Wagner et al., 2000).
Transduction efﬁciencies of replication-deﬁcient vectors were
assayed using CRFK cells grown in 24-well plates (Bastone et al.,
2007; Wagner et al., 2000).
Molecular cloning
To generate new Gag expression constructs without the FFV 5′
UTR, the gag ORF of pCF-7 (Schwantes, Ortlepp, and Löchelt, 2002)
was ampliﬁed by PCR with primers GagsAgeI and GagaBamHI (for all
primer sequences, see Supplementary Table 1) using FastStart High
Fidelity PCR System as given by the supplier (Roche, Mannheim,
Germany). The BamHI- and AgeI-digested MLV-based RD vector
pMP71-oPRE (Schambach et al., 2006a) and the PCR products were
then ligated.
pBC12 vector-based FFV Gag expression construct pBC-Gag-sp
devoid of 5′ UTR sequences but containing a splice-competent rat
pre-pro-insulin intron was constructed by PCR-mediated ampliﬁca-
tion of FFV gag sequences with primers GagsHindIIIAgeI and
GagaBamHI. The PCR product and pBC12 vector (see Bastone, Bravo,
and Löchelt, 2006) were digested with BamHI and HindIII and ligated.
pBC-Gag-sp served as vector for constructing expression clones pBC-
Gag-oPRE-sp and pBC-Gag-oPRE. For this purpose, clone pMP71Gag-
oPRE was cut with NheI, the site was blunt-ended with Klenow
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and used as insert. To construct pBC-Gag-oPRE, pBC-Gag-sp was
digested with AgeI and SmaI for insertion while pBC-Gag-sp was
incubated with AgeI and BamHI and blunt-ending of the BamHI site
was done to generate pBC-Gag-oPRE-sp.
For the FFV Pol expression plasmid pMP-Pol-oPRE, FFV pol was
ampliﬁed by PCR with primers PolsAgeI and PolaBamHI. The PCR
product and the pMP71-oPRE were digested with the same enzymes
and ligated. The resulting clone was identiﬁed by DNA sequencing.
Tomutate the 5′ SD, two central primers (SD 721 and SD 763)were
used to substitute the GU di-nucleotide to NN (randomnucleotide: N).
Flanking primers CMV-421 and SwaI-1005 were used to amplify the
two fragments separately. Subsequently fusion PCR was conducted
with the two amplicons using the primers CMV-421 and SwaI-1005.
The fusion PCR fragment was inserted into the pCF-7-ubi-lacZ
parental vector using the two unique NcoI and SwaI restriction sites.
The resulting clones were identiﬁed by DNA sequencing.
To analyze the role of the nuclear RNA export in the observed
defects of the GCmutant, the GU to GC 5′ SDmutation was introduced
into the pCF-ubi-EO vector (to be described elsewhere). For this
purpose, the GC mutant plasmid and vector pCF-ubi-EO were
digested with SalI and SphI. The corresponding fragments were
exchanged. The resulting clone was sequenced and designated pCF-
ubi-EO-GC.
PCR-mediated mutagenesis was used to inactivate the gag ATG.
By introducing a new BamHI site, the start codon ATG and ﬂanking
sequences were mutated from GGATGG to GGATCC using primer
P1391 and P1453BATCC. Alternatively, the ATG codon was randomly
mutated to ANH (N: A; T; G; C, H: A; T; C) using another reverse
primer P1453R. Two unique sites (SwaI and XhoI) were used to
insert the ATG-mutated fragment into the parental pCF-7-ubi-lacZ
vector.
Different deletions were introduced into pCF-7-ubi-lacZ and pCF-
lac-AGC derivatives while maintaining the known CAS elements. The
schematic structure of each construct and the restriction sites used
to delete sequences between the two CAS elements are depicted in
Fig. 4C. The new constructs were designated according to the
restriction sites used, for instance: ΔBB indicates that deletions
were introduced between two restriction sites (BglII and BglII). When
both ends were not compatible for ligation, Klenow was used to blunt
both termini as described by the supplier (Fermentas, St. Leon-Rot,
Germany). The sufﬁx AGC indicates that the deleted construct is
derived from the gag ATG mutant pCF-lac-AGC. To construct for
example pCF-lac AGC-ΔEB, pCF-lac-AGCwas ﬁrst digested with EcoRV
and BglII and treated with Klenow fragment before ligation.
To redeﬁne FFV CASII, ﬁve sense and three antisense PCR primers
(Supplementary Table 1) were designed to generate 500 to 700 nt-
long consecutive deletions. All sense primers contain a BglII site and
all antisense primers a SalI site. Amplicons from 0.6 kb to 2.1 kb in
length spanning the putative CASII were cloned into pCF-lac-AGC-ΔBB
using the ﬂanking BglII and SalI sites (Figs. 4C and 5A).
Real-time RT–PCR
To analyze the abundance of full-length vector genomic RNA in
vector-transfected 293T cells, real-time RT–PCR based on SYBR Green
(Invitrogen) was used to quantify the relative amounts of nuclear and
cytoplasmic total RNAs. Two days p.t., the 293T cells were washed
twice with PBS, treated with hypotonic buffer and separated in
nuclear and cytoplasmic fractions. RNAs were extracted from both
fractions separately and pre-treated with RNase-free DNaseI. UbiC
qRT–PCR primers (ubi-F: 5′-GTAGGTGTGCGGTAGGCTTT-3′, ubi-R:
5′-CTGACGCCTCACTTATCCCT-3′) target the ubiC promoter which is
present in the full-length genomic RNAs but not in ubiC promoter-
derived transcripts. GAPDH (F-primer: 5′-ATGACATCAAGAAGGTGGT-
3′, R-primer: 5′-CATACCAGGAAATGAGCTTG-3′) was ampliﬁed asinternal reference for relative quantitative analysis of full-length
RNA. Samples without reverse transcription and distilled water were
used as negative controls.
Immunoblot analyses
Transfected cells were harvested by lysis in 1% SDS. Immunoblots
were performed as previously described (Winkler et al., 1997).
Expression of Gag was analyzed using Cat serum 8014 and Gag
antisera (Alke et al., 2001; Geiselhart et al., 2003). Mouse anti-Gfp and
anti-β-actin monoclonal antibodies (Sigma, Munich, Germany) were
used as loading controls.
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